AXXAM

info@axxam.com

Science Spyglass

Empowering oncology drug discovery with Axxam’s tailored solutions

At Axxam, we are committed to advancing oncology drug discovery by applying a range of approaches designed to define molecular targets or disease mechanisms and to identify small molecule hits and lead candidates as starting points for drug development in cancer research.

We offer tailored assays and screening solutions, addressing many of the biological mechanisms underlying complex cancer hallmarks:

  • Advanced assays for biomolecular interactions: Our assay designs are based on the current structural understanding of crucial molecular mechanisms driving cancer progression, such as protein-protein or protein-DNA/RNA interactions. This enables us to identify even weakly active small molecules.
Axxam in oncology drug discovery
  • Biophysical methods for drug interaction validation: We utilize techniques such as thermal shift analysis and microscale thermophoresis to confirm and explore the interactions between compounds and their targets, ensuring precise and reliable results in oncology drug discovery.
  • Covalent binder compound collection: We have recently expanded our chemical libraries to include a library of covalent binders named AXXCovalent, with the aim of identifying lead candidates also for notoriously difficult-to-target proteins.
  • Targeted protein degradation: Axxam has developed assays to explore targeted protein degradation, particularly to address so-called “undruggable” targets like transcription factors and intrinsically disordered proteins. We have also partnered with Symeres to generate a PROTAC (proteolysis-targeting chimeras) platform enabling the identification of degraders that act via the proteasome.
  • Cellular platform techniques: Axxam uses advanced cellular assays to monitor pharmacological effects of compounds on epigenetic and transcriptional mechanisms, splicing processes, and signaling pathways. These assays are performed in physiologically relevant cell types as well as within native cellular environments.
  • High-content screening with 2D and 3D models: Axxam employs high-content screening techniques to monitor changes in the cell phenotypes, both in traditional 2D cultures and more complex 3D tumor spheroids to better simulate the tumor environment.
  • Mass spectrometry-based target identification: Through our collaboration with Momentum Biotechnologies, we employ affinity selection mass spectrometry to identify novel small molecule binders testing our AXXDiversity compound collection, targeting both protein and RNA targets.
Slide 1_Axxam in oncology drug discovery
Slide 2_supporting oncology research
Slide 3_target function and interaction
Slide 4_from pathway to phenotype
Slide 5_from pathway to phenotype
Slide 6_expanded chemical space

    Contact us
    Back
    Scroll to Top